Previous 10 | Next 10 |
home / stock / biovf / biovf news
2023-07-18 08:24:42 ET Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q2 Non-GAAP EPS of SEK1.48. Revenue of SEK4.87B (+25.8% Y/Y) misses by $419.36M . For further details see: Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK1.48, revenue of SEK4.87M m...
2023-05-10 10:51:53 ET Shares of CTI BioPharma (NASDAQ: CTIC) were up more than 80% early Wednesday after the company announced it was getting bought out for $1.7 billion by Swedish Orphan Biovitrum AB (OTC: BIOVF) , also known as SOBI. CTI BioPharma specializes in targe...
2023-04-29 10:58:09 ET Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2023 Earnings Conference Call April 27, 2023 8:00 a.m. ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Tony Hoos - Head of RDMA, Chief ...
2023-04-29 10:34:32 ET The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2023 Q1 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2023 Q1 - Results - Earnings Call Presentation
2023-04-27 12:54:50 ET Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q1 Non-GAAP EPS of SEK3.60. Revenue of SEK5.24M. For further details see: Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.60, revenue of SEK5.24M
Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB PR Newswire Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile ...
AstraZeneca ( NASDAQ: AZN ) and Sanofi's ( NASDAQ: SNY ) antibody therapy Beyfortus continues to show consistent protection against Respiratory Syncytial Virus (RSV) disease through the RSV season in infants, the British drugmaker said on Tuesday. AstraZeneca said it will...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2022 Results Conference Call February 08, 2023 07:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Anders Ullman - Head of R&D Conference Call Participants Christopher Uhde - SEB ...
Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q4 GAAP EPS of SEK 4.68. Revenue of SEK 5.99B (+22.2% Y/Y). EBITA SEK 2,455M; EBITA margin 41%. EBIT SEK 1,916M. Outlook 2023: Revenue is anticipated to grow by a low-to-mid single-digit p...
Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ), the biotech also known as Sobi, has received the FDA’s Emergency Use Authorization (EUA) for its anti-inflammatory medication Kineret as a treatment for certain hospitalized patients with COVID-19. The FDA decision was backed...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Swedish Orphan Biovitrum AB (BIOVF) is expected to report $0.09 for Q3 2023